Here we present the first comparison of inhibition of BCL-2 prosurvival proteins BCL-2, BCL-xL and MCL-1 in combination with a second or third generation TKI, crucially with comparisons drawn between myeloid and lymphoid BP-CML samples. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.